处于缓解期的BCR-ABL1阳性慢性髓性白血病患者的系统性肥大细胞增多症
Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase.
作者信息
Fokoloros Christos, Foukas Periklis, Georgakopoulos Nikolaos, Tsakiraki Zoi, Bouchla Anthi, Pappa Vasilliki, Katoulis Alexandros, Makris Michael, Papageorgiou Sotirios
机构信息
Allergy Unit "D. Kalogeromitros", 2nd Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
2nd Department of Pathology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
出版信息
Case Rep Hematol. 2022 Nov 3;2022:7251658. doi: 10.1155/2022/7251658. eCollection 2022.
Systemic mastocytosis (SM) comprises a group of rare disorders resulting from tissue infiltration by pathological mast cells. In a percentage ranging from 5 to 40% in various patient series, SM appears to be associated with an accompanying hematologic neoplasm (SM-AHN). The coexistence of SM with chronic myelogenous leukemia (CML) is extremely rare with only 3 cases in the literature. The natural course of CML has changed dramatically over the past 2 decades with the use of tyrosine kinase inhibitors (TKIs). We report a case of diagnosing SM in a patient in complete molecular remission of CML after stopping TKI treatment.
系统性肥大细胞增多症（SM）是一组由病理性肥大细胞浸润组织引起的罕见疾病。在不同患者系列中，5%至40%的病例中，SM似乎与伴发的血液系统肿瘤（SM-AHN）有关。SM与慢性粒细胞白血病（CML）共存极为罕见，文献中仅有3例报道。在过去20年中，随着酪氨酸激酶抑制剂（TKIs）的应用，CML的自然病程发生了巨大变化。我们报告了1例在停用TKI治疗后处于CML完全分子缓解期的患者被诊断为SM的病例。
Zotero 插件